2022
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.ChaptersPolycystic ovary syndromeType 2 diabetes mellitusDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGLP-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsWeight lossGLP-1 RAsCV risk factorsGlucose-lowering medicationsCotransporter 2 inhibitorsGlucose lowering medicationsPeptidase-4 inhibitorsHigh-risk populationCategories of medicationsAbnormal carbohydrate metabolismPart of standardCV outcomesLifestyle interventionOvary syndromeMetabolic sequelaeMetabolic abnormalitiesMetabolic managementSGLT2 inhibitorsPatient population
2021
ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialKidney eventsOutcome trialsPlacebo armMyocardial infarctionType 2 diabetes mellitusLower baseline eGFRMI/strokeSubsequent CV eventsRisk of hospitalizationCoronary artery diseaseType 2 diabetesHigh uric acidUse of therapiesAssociation of kidneyBaseline eGFRCV eventsCV outcomesSubsequent HHFCardiovascular outcomesHF outcomesArtery diseaseBaseline factorsDiabetes mellitusHeart failure
2019
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp